Milan exchange. Sector: Healthcare. Industry: Drug Manufacturers—Specialty & Generic. Location Italy, Pisa.

Pharmanutra S.p.A. [PHN.MIItaly

65.6USD0.6 (+0.91%)

• At close Mon Oct 03 2022

648,212,643 USD
MARKET CAP
42.297
PE
0.472
BETA (5y)
1.454
EPS

profit

392%

for 5 years

profit

288%

for 3 years

profit

182%

for 2 years

profit

74%

for 1 year

profit

-1%

for this year

About Pharmanutra S.p.A.

Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.

Pharmanutra S.p.A., nata nel 2003 a Pisa, svillupa e distribuisce complementi nutrizionali e dispositivi medici innovativi, efficaci e sicuri.

Pharmanutra S.p.A.
https://www.pharmanutra.it
© 2022 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.